Anonymous26 days ago
New research presented at the American Academy of Orthopaedic Surgeons' 2026 annual meeting links GLP-1 receptor agonist drugs like Ozempic and Wegovy to elevated risks of osteoporosis, tendon ruptures, and fragility fractures. With an estimated 10 million Americans now taking these blockbuster medications and the market projected to surpass $120 billion by 2030, orthopedic surgeons and endocrinologists are urging that bone health monitoring and structured exercise become standard components of GLP-1 therapy.